Reports
Sale
Deep Vein Thrombosis Market Size, Share, Trends, Forecast: By Drug Class: Anticoagulants, Blood Thinners, Others; By Route of Administration: Oral, Parenteral, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies; Regional Analysis; Market Dynamics: SWOT Analysis; Supplier Landscape; 2024-2032
Deep Vein Thrombosis Market Size
The deep vein thrombosis market was valued at USD 885.63 million in 2023, driven by the increasing cases of deep vein thrombosis and advancements in treatment options across the 8 major markets. The market is expected to grow at a CAGR of 6.45% during the forecast period of 2024-2032, with the values likely to reach USD 1271.93 million by 2032.
Deep Vein Thrombosis Market Outlook
- The high incidence of deep vein thrombosis and the growing elderly population more prone to developing the condition is expected to drive the demand for deep vein thrombosis treatment and diagnostic services.
- The rising advancements in pharmacological and non-pharmacological treatment options to manage deep vein thrombosis are poised to elevate the market value.
- The increasing availability of generic drugs and the growing demand for minimally invasive procedures are key trends set to shape the market dynamics.
Deep Vein Thrombosis Market Overview
In deep vein thrombosis (DVT), a blood clot is formed within the deep veins, usually occurring in the leg but can also form in the mesenteric and cerebral veins and the arms. This disease, accounting for the majority of pulmonary embolism, is considered the third most common cause of mortality from a cardiovascular condition. In the United States, the incidence and risk of complications associated with deep vein thrombosis are found to be higher in white people and African Americans compared to Asians and Hispanics. Additionally, older adults over the age of 40 years are more susceptible to developing the condition.
The deep vein thrombosis market is driven by the rising advancements in pharmacological and non-pharmacological treatment options, including the development of novel anticoagulants, mechanical thrombectomy devices, and compression therapies. Innovations in diagnostic technologies, such as Doppler ultrasound and D-dimer tests, also support market expansion by facilitating early diagnosis of the disease. Intensive research activities and clinical trials aimed at developing new therapeutic approaches to manage deep vein thrombosis are further expected to bolster the market share in the forecast period.
Deep Vein Thrombosis Market Growth Drivers
Growing Burden of Deep Vein Thrombosis is Expected to Drive Market Growth
Recent data suggests that 80 new cases of deep vein thrombosis per 100,000 population are estimated to occur every year. Around 1 in 20 individuals develop the condition during the course of their lifetime. In the United States, approximately 600,000 hospitalizations occur due to this disease annually. The high incidence of deep vein thrombosis is poised to amplify the market demand for effective therapies. Moreover, it is reported that the incidence of venous thrombosis in elderly people increases by four-fold. Thus, the growing aging population is projected to be a major growth driver of the market.
Rising Introduction of Generic Drugs to Meet Deep Vein Thrombosis Market Demand
The rising introduction of generic drugs in the market is making deep vein thrombosis treatments more affordable and accessible. For instance, in June 2024, Indian multinational pharmaceutical company Alembic Pharmaceuticals received the U.S. Food and Drug Administration (FDA) clearance for its Abbreviated New Drug Application (ANDA) for Dabigatran Etexilate Capsules, 75 mg and 150 mg as well as a Tentative approval for Dabigatran Etexilate Capsules, 110 mg. Dabigatran Etexilate Capsules are therapeutically equivalent to Boehringer Ingelheim Pharmaceuticals' Pradaxa Capsules and are indicated for treatment and reduction in the risk of recurrence of deep venous thrombosis in adult patients.
Additionally, in January 2024, India-based generic drug manufacturer Lupin Limited was granted Tentative approval for its Rivaroxaban Tablets (the generic equivalent of Xarelto® Tablets developed by Johnson & Johnson Innovative Medicine), which can help in the treatment of deep vein thrombosis. The rising entry of generic drugs is anticipated to aid market growth along with improving treatment adherence and outcomes.
Deep Vein Thrombosis Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Shift Towards Novel Oral Anticoagulants (NOACs) | One of the major market trends is the increased adoption of new oral anticoagulants (NOACs) such as rivaroxaban, edoxaban, apixaban, and dabigatran, to treat venous thromboembolism, owing to their rapid onset of action and reduced need for regular monitoring. |
| Growing Demand for Minimally Invasive Treatment Techniques | The market benefits from the growing adoption of minimally invasive procedures, such as catheter-directed thrombolysis and mechanical thrombectomy. The advances in such procedures lead to shorter recovery times as well as minimize the risk of complications and thus enhance patient outcomes. |
| Pharmaceutical Developments | The deep vein thrombosis market share is positively impacted by the rising advancements in anticoagulant therapies and other medications for preventing and treating this medical condition. Pharmaceutical companies are increasingly investing in the development of new drug formulations with improved efficacy and safety, which is poised to fuel market growth. |
| Heightened Public Awareness | There is a growing awareness regarding the risks, symptoms, treatment, and prevention of deep vein thrombosis among the general population and healthcare providers which is influencing the market dynamics. This heightened patient awareness is leading to early diagnosis and treatment, thereby augmenting the market demand. |
Deep Vein Thrombosis Market Segmentation
Market Breakup by Drug Class
- Anticoagulants
- Blood Thinners
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Deep Vein Thrombosis Market Share
Market Segmentation Based on Drug Class is Anticipated to Witness Substantial Growth
Based on the drug class, the market is segmented into anticoagulants, blood thinners, and others. The anticoagulant segment represents a substantial share of the market and includes medications that prevent blood clot formation by inhibiting various factors in the blood coagulation process. Anticoagulants can be taken either via oral (warfarin, rivaroxaban, and apixaban) or by injectable route (enoxaparin and fondaparinux). The availability of strong clinical evidence in favor of the efficacy of anticoagulants in the prevention and treatment of deep vein thrombosis makes them the preferred choice among patients.
Deep Vein Thrombosis Market Analysis by Region
Based on the region, the market report includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share due to the rising burden of deep vein thrombosis, which can be attributed to the growing prevalence of risk factors such as sedentary lifestyle and obesity. High healthcare expenditure and the presence of advanced diagnostic and treatment technologies are some of the factors poised to bolster market growth in the region. With the rising improvements in healthcare systems, emerging markets such as India are anticipated to witness exponential market growth supported by increasing investments in healthcare infrastructure and services and the growing awareness of deep vein thrombosis.
Leading Players in the Deep Vein Thrombosis Market
The key features of the market report comprise patent analysis, clinical trial analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Aspen Pharmacare Holdings Ltd
Global speciality and branded pharmaceutical company Aspen Pharmacare Holdings Ltd is headquartered in South Africa and plays a prominent role in the market. The company specializes in preventing and treating thrombotic diseases such as deep vein thrombosis through its anticoagulant thrombosis products.
Novartis AG
Swiss company Novartis AG is considered one of the world's largest manufacturers of pharmaceuticals. It offers anticoagulants such as enoxaparin and other cardiovascular medicines that help in managing deep vein thrombosis.
Mylan N.V.
Mylan N.V., now a part of Viatris Inc. after merging with a division of Pfizer (Upjohn), boasts a robust portfolio of generic and specialty pharmaceuticals. Mylan is known to actively engage in strategic partnerships to expand its product offerings and plays a significant role in the deep vein thrombosis market growth.
Momenta Pharmaceuticals, Inc.
Biopharmaceutical company Momenta Pharmaceuticals, Inc. is headquartered in Massachusetts, United States, and is one of the key players in the market. It is known for its expertise in manufacturing complex generics including anticoagulants for treating deep vein thrombosis.
Other key players in the market include Hikma Pharmaceuticals PLC, G.L. Pharma GmbH, Cobapharma S.L.U, Boehringer Ingelheim GmbH, Glenmark Pharmaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Johnson & Johnson Services, Inc., and Bayer AG among others.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Deep Vein Thrombosis Market Report
- What was the deep vein thrombosis market value in 2023?
- What is the deep vein thrombosis market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on drug class?
- What is the market breakup based on the route of administration?
- What are the major distribution channels in the market?
- What are the major factors aiding the deep vein thrombosis market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of deep vein thrombosis diseases affect the market landscape?
- What are the major deep vein thrombosis market trends?
- How does the advancement in treatment options impact the market size?
- Which drug class will dominate the market share?
- Which route of administration is expected to have a high market value in the coming years?
- Which distribution channel is projected to contribute to the highest market growth?
- Who are the key players involved in the deep vein thrombosis market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Deep Vein Thrombosis Market Overview: 8 Major Market
3.1 Deep Vein Thrombosis Market Historical Value (2017-2023)
3.2 Deep Vein Thrombosis Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Deep Vein Thrombosis: Disease Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Therapy Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Therapy Success Rate
7 Deep Vein Thrombosis Market Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2017-2032)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Deep Vein Thrombosis Market Landscape: 8 Major Market*
8.1 Deep Vein Thrombosis Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Deep Vein Thrombosis Market: Product Landscape
8.2.1 Analysis by Drug Class
8.2.2 Analysis by Route of Administration
9 Deep Vein Thrombosis Market Therapy Challenges and Unmet Needs
9.1 Therapy Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Therapy
11 Global Deep Vein Thrombosis: Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Deep Vein Thrombosis Market Segmentation: 8 Major Market
12.1 Deep Vein Thrombosis Market by Drug Class
12.1.1 Market Overview
12.1.2 Anticoagulants
12.1.3 Blood Thinners
12.1.4 Others
12.2 Deep Vein Thrombosis Market by Route of Administration
12.2.1 Market Overview
12.2.2 Oral
12.2.3 Parenteral
12.2.4 Others
12.3 Deep Vein Thrombosis Market by Distribution Channel
12.3.1 Market Overview
12.3.2 Hospital Pharmacies
12.3.3 Retail Pharmacies
12.3.4 Online Pharmacies
12.4 Deep Vein Thrombosis Market by Region
12.4.1 Market Overview
12.4.2 United States
12.4.3 EU-4 and the United Kingdom
12.4.3.1 Germany
12.4.3.2 France
12.4.3.3 Italy
12.4.3.4 Spain
12.4.3.5 United Kingdom
12.4.4 Japan
12.4.5 India
13 United States Deep Vein Thrombosis Market (2017-2032)
13.1 United States Deep Vein Thrombosis Market Historical Value (2017-2023)
13.2 United States Deep Vein Thrombosis Market Forecast Value (2024-2032)
13.3 United States Deep Vein Thrombosis Market by Drug Class
13.3.1 Market Overview
13.3.2 Anticoagulants
13.3.3 Blood Thinners
13.3.4 Others
13.4 United States Deep Vein Thrombosis Market by Route of Administration
13.4.1 Market Overview
13.4.2 Oral
13.4.3 Parenteral
13.4.4 Others
13.5 United States Deep Vein Thrombosis Market by Distribution Channel
13.5.1 Market Overview
13.5.2 Hospital Pharmacies
13.5.3 Retail Pharmacies
13.5.4 Online Pharmacies
14 EU-4 and United Kingdom Deep Vein Thrombosis Market (2017-2032)
14.1 EU-4 and United Kingdom Deep Vein Thrombosis Market Historical Value (2017-2023)
14.2 EU-4 and United Kingdom Deep Vein Thrombosis Market Forecast Value (2024-2032)
14.3 EU-4 and United Kingdom Deep Vein Thrombosis Market by Drug Class
14.3.1 Market Overview
14.3.2 Anticoagulants
14.3.3 Blood Thinners
14.3.4 Others
14.4 EU-4 and United Kingdom Deep Vein Thrombosis Market by Route of Administration
14.4.1 Market Overview
14.4.2 Oral
14.4.3 Parenteral
14.4.4 Others
14.5 EU-4 and United Kingdom Deep Vein Thrombosis Market by Distribution Channel
14.5.1 Market Overview
14.5.2 Hospital Pharmacies
14.5.3 Retail Pharmacies
14.5.4 Online Pharmacies
15 Japan Deep Vein Thrombosis Market
15.1 Japan Deep Vein Thrombosis Market Historical Value (2017-2023)
15.2 Japan Deep Vein Thrombosis Market Forecast Value (2024-2032)
15.3 Japan Deep Vein Thrombosis Market by Drug Class
15.3.1 Market Overview
15.3.2 Anticoagulants
15.3.3 Blood Thinners
15.3.4 Others
15.4 Japan Deep Vein Thrombosis Market by Route of Administration
15.4.1 Market Overview
15.4.2 Oral
15.4.3 Parenteral
15.4.4 Others
15.5 Japan Deep Vein Thrombosis Market by Distribution Channel
15.5.1 Market Overview
15.5.2 Hospital Pharmacies
15.5.3 Retail Pharmacies
15.5.4 Online Pharmacies
16 India Deep Vein Thrombosis Market
16.1 India Deep Vein Thrombosis Market (2017-2032) Historical Value (2017-2023)
16.2 India Deep Vein Thrombosis Market (2017-2032) Forecast Value (2024-2032)
16.3 India Deep Vein Thrombosis Market by Drug Class
16.3.1 Market Overview
16.3.2 Anticoagulants
16.3.3 Blood Thinners
16.3.4 Others
16.4 India Deep Vein Thrombosis Market by Route of Administration
16.4.1 Market Overview
16.4.2 Oral
16.4.3 Parenteral
16.4.4 Others
16.5 India Deep Vein Thrombosis Market by Distribution Channel
16.5.1 Market Overview
16.5.2 Hospital Pharmacies
16.5.3 Retail Pharmacies
16.5.4 Online Pharmacies
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 INDIA CDSCO
17.5 JAPAN PMDA
17.6 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Clinical Trial Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Strategic Initiatives
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Market Share by Top 5 Companies
21.2 Aspen Pharmacare Holdings Ltd
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Novartis AG
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Mylan N.V
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Momenta Pharmaceuticals, Inc.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Hikma Pharmaceuticals PLC
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 G.L. Pharma GmbH
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Cobapharma S.L.U
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Boehringer Ingelheim GmbH
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Glenmark Pharmaceuticals Inc.
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Bristol-Myers Squibb Company
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Daiichi Sankyo Company, Limited
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Johnson & Johnson Services, Inc.
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Bayer AG
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
22 Deep Vein Thrombosis Market – Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER